Postmenopausal estrogen replacement therapy is associated with adverse breast cancer prognostic indices

Journal of Women's Health and Gender-Based Medicine

Volumn 8, Issue 6, 1999, Pages 815-823

  LeBlanc, Erin S ^a   Viscoli, Catherine M ^b   Henrich, Janet B ^b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RISK ASSESSMENT; TUMOR BIOPSY; TUMOR VOLUME;

EID: 0032865226     PISSN: 15246094     EISSN: None     Source Type: Journal    
DOI: 10.1089/152460999319138     Document Type: Article

References (31)

1. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016.
2. Antunes CM, Stolley PD, Rosenshein NB, et al. Endometrial cancer and estrogen use. N Engl J Med 1979;300:9.
3. Hulka BS, Kaufman DG, Fowler WC, Grimson RC, Greenberg BG. Predominance of early endometrial cancers after long-term estrogen use. JAMA 1980;244: 2419.
4. Brinton LA, Hoover R, Raumeni JF Jr. Menopausal oestrogens and breast cancer risk: An expanded case-control study. Br J Cancer 1986;54:825.
5. Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987;94:620.
6. Strickland DM, Gambrell RD Jr, Butzin CA, Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992;80(3 pt 1):400.
7. Gambrell RD Jr. Proposal to decrease the risk and improve the prognosis of breast cancer. Am J Obstet Gynecol 1984;150:119.
8. Jones C, Ingram D, Mattes E, Hahnel R. The effect of hormone replacement therapy on prognostic indices in women with breast cancer. Med J Aust 1994;161: 106.
9. Gambrell RD Jr. Hormone replacement therapy and breast cancer risk. Arch Fam Med 1996;5:341.
10. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer. Cancer Causes Control 1994;5:491.
11. Squitieri R, Tartter PI, Ahmed S, Brower ST, Theise ND. Carcinoma of the breast in postmenopausal hormone users and nonuser control groups. J Am Coll Surg 1994;178:167.
12. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995;85:11.
13. Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I. Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 1996;38:325.
14. Harding C, Knox WF, Faragher EB, Baildam A, Bundred NJ. Hormone replacement therapy and tumour grade in breast cancer: Prospective study in screening unit. Br Med J 1996;312:1646.
15. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: An updated analysis. Br J Obstet Gynaecol 1990;97:1080.
16. Colditz GA, Stampfer MJ, Willett WC, Hennekens CH, Rosner B, Speizer FE. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 1990;264:2648.
17. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75.
18. Burch JC, Byrd BF, Vaughn WK. Results of estrogen treatment in one thousand hysterectomized women for 14,318 years. In: van Keep PA, Greenblatt RB, Albeaux-Fernet M, eds. Consensus on menopausal research: A summary of international opinion: The proceedings of the first International Congress on the Menopause, held at La Grande Motte, France in June, 1976, under the auspices of the American Geriatric Society and the Medical Faculty of the University of Montpellier. Lancaster, England: MTP Press Ltd, 1976:164.
19. Bergkvist L, Adami HO, Persson I, et al. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989;130:221.
20. Colditz GA, Stampfer MJ, Willett WC, et al. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control 1992;3:433.
21. Willis DB, Calle EE, Miracle-McMahill HW, Heath CW. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996;7:449.
22. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769.
23. King WJ, DeSambre ER, Jensen EV, Greene GL. Comparison of immunocytochemical and steroid-binding assays for estrogen receptors in human breast tumors. Cancer Res 1985;45:293.
24. Lonning PE, Helle SI, Johannessen DC, Ekse D, Adlercreutz H. Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Res Treat 1996;39:335.
25. Elledge RM, Clark GM, Channess GC, Osborne CK. Tumor biological factors and breast cancer prognosis among white, Hispanic, and black women in US. J Natl Cancer Inst 1994;86:705.
26. Gordon NH, Crowe JP, Brumberg DJ, Berger NA. Socioeconomic factors and race in breast cancer recurrence and survival. Am J Epidemiol 1992;135:609.
27. Scalley EK, Henrich JB. An overview of estrogen replacement therapy in postmenopausal women. J Women's Health 1993;2:289.
28. Wong WW, Vijayakumas S, Weichselbaum RR. Prognostic indicators in node-negative early stage breast cancer. Am J Med 1992;92:539.
29. Figueroa JA, Yee D, McGuire WL. Prognostic indicators in early breast cancer. Am J Med Sci 1993;305:176.
30. Chadha M, Chabon AB, Friedmann P, Vikrhan V. Predictors of axillary lymph node metastases in patients with T1 breast cancer. Cancer 1994;73:350.
31. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol b-06. J Clin Oncol 1988;6:1076.